David A. Rosa Purchases 100,000 Shares of NeuroOne Medical Technologies Co. (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) CEO David A. Rosa bought 100,000 shares of NeuroOne Medical Technologies stock in a transaction that occurred on Friday, April 4th. The shares were acquired at an average price of $0.50 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,161,289 shares of the company’s stock, valued at $580,644.50. This represents a 9.42 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ:NMTC opened at $0.43 on Thursday. The stock has a market capitalization of $13.27 million, a price-to-earnings ratio of -1.65 and a beta of 0.61. NeuroOne Medical Technologies Co. has a 1-year low of $0.40 and a 1-year high of $1.39. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $0.92.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.06 EPS for the quarter. NeuroOne Medical Technologies had a negative net margin of 82.17% and a negative return on equity of 270.70%.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its holdings in shares of NeuroOne Medical Technologies by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 311,659 shares of the company’s stock valued at $257,000 after purchasing an additional 27,804 shares in the last quarter. Jane Street Group LLC bought a new position in shares of NeuroOne Medical Technologies during the 4th quarter valued at $33,000. Finally, XTX Topco Ltd bought a new position in shares of NeuroOne Medical Technologies during the 3rd quarter valued at $26,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.